Built from weaker models, sales multiples or analyst targets, so treat it as a rough guide.
Not used by alerts or posts.
Valued as a loss-making company: Sales comps and Analyst consensus.
ACCE opinionTriSalus Life Sciences Inc. Common Stock (TLSI)
Fair value
Not available
ACCE price target
$4.00
Rating
Not rated
Horizon
12 months
ACCE price target published on 15 Oct 2026, 00:00 CEST.
Price used: $3.59 at the close on 23 Oct 2026, 22:00 CEST.
Models: Analyst consensus and Sales comps.
Fair value: the average of the applicable valuation models (discounted cash flow, multiples, residual income, dividend discount, shareholder yield), each run on the latest financial statements and the market price shown. Opinion columns (fair value, target, rating) are shown apart from the data. Full methodology: acceinvestments.com/data/how-we-value-stocks
Conflicts of interest: The author holds no personal position in this security. General statement
Produced by ACCE Investments (acceinvestments.com)
Data
ACCE score
20
out of 100
Analysts
100% buy
5 covering
P/E
0.0x
forward 0.0x
1-year return
-30.0%
Dividend yield
0.00%
TriSalus Life Sciences Inc. Common Stock in four questions
Plain answers, details below
Free accounts get 5 full stock pages a month, including the four answers.
Overview
ACCE thesis
TriSalus Life Sciences makes the SIRTeX and related drug-delivery systems used in interventional oncology, with an 85.8% gross margin that shows the device economics work once a unit is in the field. The problem is scale: revenue growth is just 1.7%, and an operating margin of -86.0% means the company is spending close to two dollars for every dollar it books. A score of 26/100 and a return on equity of -496.2% reflect a business that has not yet converted its installed base into earnings. The structural tailwind is a procedure market where the product's margin profile would be valuable if sales volume rose sharply, but the data here shows no accelerating top line to support that. At a $240M market cap with no index membership and no positive earnings, the name is a candidate only for a diligence file that tests whether the cost base can come down before the cash runway matters.
⚠ Investor warnings · 3 flagsAI-assisted·How I use AI
severe
Cash burn outpaces market value
Free cash flow was -$18.9M against a $250M market cap, with operating margin at -86.0% and net margin at -62.6%. Debt/equity of -1.02 signals negative book equity, so balance sheet strength needs direct verification.
high
Revenue growth stalled
Revenue grew only 1.7% year over year and fell 13.6% quarter over quarter, far below the 52.3% five-year CAGR. The recent slowdown is the key signal, not the historical record.
moderate
Elevated short interest
Short interest sits at 7.2% of float. That is a meaningful level of bearish positioning and adds volatility risk around any news.
AI research notes
AI-assisted·How I use AIWritten Oct 13, 2026 · figures from 2026-06-30 · prices to Oct 23, 2026
Why it could do well
Analysts are unanimous, with all five covering analysts rating the stock Buy or Strong Buy.
The average analyst price target of $10.40 sits well above the $4.14 share price.
Revenue has grown by 52.3% a year on average over five years, showing a long record of expansion.
Why it could disappoint
Net margin of -62.6% means the company loses far more than it earns on each dollar of sales.
Free cash flow over the last twelve months was -$19M, so the business is burning cash rather than generating it.
The diluted share count rose 43.0% last fiscal year, diluting existing shareholders' stake in the company.
Each chip shows the exact figure and where it comes from. A claim without a source is not published.
Next results
Nov 10, 2026
We update the fair value about 2 days after the results, once the new figures are filed.Add to calendarGoogle
Walk me through this stock
Plain-English pros, cons, and what to watch. Pro feature.
PRO
Ask ACCE
Valuation
INVESTOR
Where TLSI's valuation models land
Price
$3.59
Model fair valueConfidence: low
about $6.90
Model
Fair value
Upside
Analyst consensus
Sales comps
Create a free account: 5 full stock pages a month, no card.
See what each model says, the assumptions behind it, the bad, normal and good cases, and why the fair value changed.
Quality
INVESTOR
Quality and conviction INVESTOR FEATURE
The full quality picture: a reason under every score, how the scores moved, and the conviction breakdown.
+A plain reason under every score
+Conviction breakdown and growth / value / quality / momentum scores